This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
(MedPage Today) -- The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk patients with type 2 diabetes (T2D), chronic kidneydisease (CKD), and cardiovascular risk factors, a prespecified.
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidneydisease with additional cardiovascular risk factors, can significantly reduce heart attack and stroke among these patients, according to results from an international clinical trial led by a Mount Sinai researcher.
Objective To explore trends in prognosis and use of glucose-lowering drugs (GLD) in patients with diabetes and coronary artery disease (CAD). Research design and methods All patients with diabetes and CAD undergoing a coronary angiography between 2010 and 2021 according to the Swedish Angiography and Angioplasty Registry were included.
Stroke, Volume 55, Issue Suppl_1 , Page AWP278-AWP278, February 1, 2024. Background:The current AHA stroke prevention guidelines give Class 1 recommendations that patients with AIS and diabetes should receive glucose-lowering agents with cardiovascular benefit to reduce risk of MACE.
Background:The Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) trial showed cardiovascular disease (CVD) benefits of semaglutide therapy in patients with type 2 diabetes mellitus (T2DM).Purpose:To year follow-up time).Results:Among
Stroke, Volume 56, Issue Suppl_1 , Page AWP294-AWP294, February 1, 2025. Background:Racial disparities have been well described in cardiovascular disease. IE patients were having a comparable risk of ischemic stroke among both the races after 1 month (RR, 1.17 (95% CI: 0.96-1.42), Both groups were followed for 12 months.
Stroke, Volume 55, Issue Suppl_1 , Page A52-A52, February 1, 2024. Background/Purpose:Stroke imposes a substantial healthcare burden, with ischemic stroke (IS) mortality rising from 2.04 million by 2030 according to the Global Burden of Disease Study. to 2.26) and liver disease (OR 2.20, p < 0.01, CI 1.27
AFib causes a variety of symptoms, including fast or chaotic heartbeat, fatigue, shortness of breath, and chest pain, and causes about 450,000 hospitalizations each year, according to the Centers for Disease Control and Prevention. For example, kidneydisease is not included in CHA 2 DS 2 -VASc.
Stroke, Volume 56, Issue Suppl_1 , Page A49-A49, February 1, 2025. Hypertension, diabetes, hyperlipidemia, and chronic kidneydisease are well-known cardiovascular risk factors for ICH. Introduction:Intracranial hemorrhage (ICH) is the most severe adverse effect of anticoagulation in atrial fibrillation (AF) patients.
of patients had cardiovascular disease, 10.9% diabetes, and 15.5% chronic kidneydisease. and I2= 43%, p = 0.15) and low for stroke (I2 = 0%, p = 0.70). The results were reported as the pooled results using risk ratio (RR) and a confidence interval (CI) of 95%.Results:The and I2 = 0%, p = 0.44).
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. Risk factors such as smoking, chronic kidneydisease, and aging can contribute to plaque formation. Risk factors such as smoking, chronic kidneydisease, and aging can contribute to plaque formation.
2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidneydisease (CKD). A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic KidneyDisease (FIND-CKD). 4 Approximately 6.7 million adults in the U.S.
Efficacy and safety of finerenone in patients with chronic kidneydisease and type 2 diabetes by diuretic use: a FIDELITY analysis. b Composite of time to CV death, non-fatal MI, non-fatal stroke, or HHF. a If patients were receiving both types of diuretics at baseline, they were included in both subgroups.
Atrial fibrillation, a rapid, irregular heart beat that can lead to stroke or sudden death, is three times more common than previously thought, affecting nearly 5 percent of the population, or 10.5 Studies have shown that people with A-Fib are up to 5 times more likely to have a stroke. tim.hodson Wed, 09/11/2024 - 15:40 Sept.
Stroke, Volume 56, Issue Suppl_1 , Page AWP289-AWP289, February 1, 2025. Background:The ABCD-GENE score, incorporating age, body mass index, chronic kidneydisease, diabetes, and CYP2C19 genotypes, is a validated risk score that integrates clinical risk factors with genetic information to predict clopidogrel response.
We aimed to determine whether selfreported risk factors serve as reliable proxies and predict stroke and dementiarelated mortality.Methods and ResultsWe used crosssectional data from the NHANES (National Health and Nutrition Examination Survey) from 1999 to 2018 linked to National Death Index records.
Heart Disease in 2050 – The AHA warned of massive heart disease increases by 2050, spanning CVD (+60%), diabetes (+100%), obesity (+70%), hypertension (+44%), heart failure (+66%), and stroke (+100%). Add all that up and the cost of treating adult CVD and stroke patients will increase by 195% to $1.85
Stroke, Volume 56, Issue Suppl_1 , Page AWP319-AWP319, February 1, 2025. Reliability of self-reported risk factors was high in overweight (F1 0.81) and diabetes (F1 0.71), moderate in hearing impairment (F1 0.59) and hypertension (F1 0.56) and low in hypercholesterolemia (F1 0.49) and kidneydisease (F1 0.25).
This leaves a gap in the care of these patients and increases their risk for heart attack, stroke and heart failure progression. HTN accelerates the progression of atherosclerosis and leads to increased risk of major cardiac events like heart attack, heart failure, kidneydisease and other end organ damage. Circulation.
Stroke, Volume 56, Issue Suppl_1 , Page ADP47-ADP47, February 1, 2025. Introduction:Chronic kidneydisease (CKD) is a risk factor for intracerebral hemorrhage (ICH) and for worse outcomes following ICH.
High blood pressure, or hypertension , is a leading cause of heart attacks, strokes and death. Centers for Disease Control and Prevention (CDC) estimates that nearly half of U.S. Approximately 1 in 4 patients had diabetes other than Type 1 in addition to high blood pressure. No new serious safety concerns were observed.”
Stroke, Volume 55, Issue Suppl_1 , Page AWP160-AWP160, February 1, 2024. Introduction:Chronic kidneydisease (CKD) is a risk factor for intracerebral hemorrhage (ICH) and for worse outcomes following ICH.
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. Study Population includes all patients with an ischemic stroke inpatient admission in 2018 and were continuously enrolled with Medicare FFS for 1 year prior to and following their initial 2018 stroke admission.
Atrial fibrillation, a rapid, irregular heart beat that can lead to stroke or sudden death, is three times more common than previously thought, affecting nearly 5 percent of the population, or 10.5 Studies have shown that people with A-Fib are up to 5 times more likely to have a stroke. tim.hodson Wed, 09/11/2024 - 15:40 Sept.
Stroke, Volume 55, Issue Suppl_1 , Page AWP269-AWP269, February 1, 2024. This study aims to assess sociodemographic profile and stroke risk factors among individuals residing in FDs within the predominantly rural state of South Carolina (SC).Methods:Deidentified were classified as residing within a USDA defined FD.
February 2024 FDA Approvals: Innovations in Cardiovascular Interventions XACT Carotid Stent System (Approved: 02/07/2024) This approval expands the indications to be used during a Transcarotid Artery Revascularization (TCAR) procedure to prevent future strokes. Until this historic approval, no treatment existed.
Stroke, Volume 55, Issue Suppl_1 , Page ATP205-ATP205, February 1, 2024. Background and Purpose:Large vessel occlusion secondary to intracranial atherosclerotic disease (ICAD-LVO) has an estimated prevalence of 10-30%. Patient- and hospital-level characteristics were analyzed. women; mean age, 69.1 [SD, women; mean age, 69.1 [SD,
To compare the efficacy of SGLT2 inhibitors among non-older and older patients we have searched PubMed, Cochrane Central, and Embase until February 2023 for randomized controlled trials (RCTs) investigating SGLT2 inhibitors in older (age 65 years) patients with diabetes mellitus, chronic kidneydisease, and chronic heart failure.
Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1]
A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heart attack, stroke and death for people with Peripheral Artery Disease (PAD).
Stroke, Volume 56, Issue Suppl_1 , Page A102-A102, February 1, 2025. Background and Purpose:Chronic kidneydisease (CKD) is associated with an increased risk of stroke and worse outcomes, yet it is often asymptomatic, with an estimated 90% of individuals unaware they have CKD until its later stages. female, 22.1%
Stroke, Volume 56, Issue Suppl_1 , Page AWP301-AWP301, February 1, 2025. VRFs included hypertension, diabetes, kidneydisease, smoking, drug or alcohol abuse, antithrombotic medication use, and sleep apnea. Introduction:While intracranial hemorrhage (ICH) is uncommon in young adults (18-55), its incidence is on the rise.
Study end points include mortality, cardiovascular events (hospitalization for acute myocardial infarction or stroke) and limb events (hospitalization for critical limb ischemia or major amputation) and were identified using Veterans Affairs and nonVeterans Affairs encounters.ResultsThe mean age was 70.6 were male, and 18.5% At 1 year, 9.4%
BACKGROUND:Advanced chronic kidneydisease is associated with high cardiovascular risk, even after kidney transplant. METHODS:We retrospectively followed patients who underwent MPI before kidney transplant for the occurrence of MACE after transplant including myocardial infarction, stroke, heart failure, and cardiac death.
Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3
Background:Empagliflozin is a sodium glucose co-transporter 2 inhibitor that improves cardiovascular outcomes in patients with type 2 diabetes mellitus, chronic kidneydisease and heart failure. Circulation, Volume 150, Issue Suppl_1 , Page A4121215-A4121215, November 12, 2024.
Objective Risk-guided atrial fibrillation (AF) screening may be an opportunity to prevent adverse events in addition to stroke. We compared events rates for new diagnoses of cardio-renal-metabolic diseases and death in individuals identified at higher versus lower-predicted AF risk. to 13.01; 4.06), diabetes mellitus (123.3;
CABANA Trial randomized 2204 patients with AF aged 65 years or more and those below 65 years with one or more risk factors for stroke for catheter ablation with pulmonary vein ablation or drug therapy with rate or rhythm control. Among the subjects of CABANA trial 35% had NYHA class above II at baseline. 2019 Apr 2;321(13):1261-1274.
Stroke, Volume 56, Issue Suppl_1 , Page ATP360-ATP360, February 1, 2025. Introduction:Infections account for one-third of stroke deaths. Furthermore, age and chronic kidneydisease in patients with acute ischemic stroke were associated with elevated kynurenine levels. female; with PSI: 62.5% IQR 6-7; p=0.03).
CVD included stroke, congestive heart failure, coronary heart disease, and angina. Compared with participants without asthma, the prevalence of stroke in those with asthma was increased by 1.607 times; the prevalence of congestive heart failure was increased by 1.911 times.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content